

Nesrin Mogulkoc

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8076781/publications.pdf>

Version: 2024-02-01

58
papers

1,682
citations

516710

16
h-index

345221

36
g-index

58
all docs

58
docs citations

58
times ranked

1782
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial). American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1084-1092.	5.6	10
2	Temporal progression of mediastinal lymphadenopathy in idiopathic pulmonary fibrosis. European Respiratory Journal, 2022, 59, 2200024.	6.7	1
3	The DIAMORFOSIS (DIAGnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus. ERJ Open Research, 2021, 7, 00529-2020.	2.6	22
4	Development and Validation of a Clinical Diagnostic Scoring System for the Diagnosis of IPF. Annals of the American Thoracic Society, 2021, 18, 1803-1810.	3.2	2
5	Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?. European Respiratory Review, 2021, 30, 210026.	7.1	17
6	Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study. Journal of Heart and Lung Transplantation, 2021, 40, 494-503.	0.6	20
7	Mortality in combined pulmonary fibrosis and emphysema patients is determined by the sum of pulmonary fibrosis and emphysema. ERJ Open Research, 2021, 7, 00316-2021.	2.6	6
8	Pleuroparenchymal fibroelastosis in idiopathic pulmonary fibrosis: Survival analysis using visual and computer-based computed tomography assessment. EClinicalMedicine, 2021, 38, 101009.	7.1	6
9	Differences in Baseline Characteristics and Access to Treatment of Newly Diagnosed Patients With IPF in the EMPIRE Countries. Frontiers in Medicine, 2021, 8, 729203.	2.6	5
10	Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE. Drug Safety, 2020, 43, 971-980.	3.2	13
11	Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome. Thorax, 2020, 75, 648-654.	5.6	26
12	The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2020, 170, 106068.	2.9	16
13	The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis. Respiratory Research, 2020, 21, 11.	3.6	42
14	Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis. Open Respiratory Medicine Journal, 2020, 14, 22-31.	0.4	21
15	Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry. , 2020, , .		0
16	Right ventricular function in patients with pulmonary arterial hypertension associated with congenital heart disease with repaired and unrepaired defects; correlation of speckle tracking, conventional echocardiography and clinical parameters. Anatolian Journal of Cardiology, 2020, 23, 277-287.	0.9	3
17	The effect of metformin on clinically relevant outcomes in 3,144 IPF patients from the EMPIRE registry. , 2020, , .		0
18	Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respiratory Medicine, the, 2019, 7, 780-790.	10.7	139

#	ARTICLE	IF	CITATIONS
19	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 199-208.	5.6	90
20	Differences between ANCA positive and negative lung fibrosis cases without vasculitis. , 2019, , .		1
21	Effects of cardiopulmonary rehabilitation on pulmonary arterial hypertension: A prospective, randomized study. Turkish Journal of Physical Medicine and Rehabilitation, 2019, 65, 278-286.	1.1	6
22	Long-term overall survival and progression-free survival in idiopathic pulmonary fibrosis treated by pirfenidone or nintedanib or their switch. Real world data from the EMPIRE registry. , 2019, , .		2
23	Real world idiopathic pulmonary fibrosis in the EMPIRE registry. , 2018, , .		2
24	Differences in baseline characteristics of newly diagnosed IPF patents in the EMPIRE countries. , 2018, , .		1
25	Bleeding risk in IPF patients treated with different anticoagulants:Real world data from the European MultiPartner IPF Registry (EMPIRE). , 2018, , .		1
26	Comorbid conditions in IPF patients; their frequencies and impacts on survival. , 2018, , .		0
27	Does body mass index have prognostic significance for patients with idiopathic pulmonary fibrosis?. , 2018, , .		2
28	Does body mass index influence survival of patients with idiopathic pulmonary fibrosis?. , 2018, , .		0
29	Right ventricular freeâ€wall longitudinal speckle tracking strain in patients with pulmonary arterial hypertension under specific treatment. Echocardiography, 2017, 34, 530-536.	0.9	12
30	Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. Lancet Respiratory Medicine,the, 2017, 5, 591-598.	10.7	71
31	RISE-IIP: Riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia. , 2017, , .		4
32	Does timeliness of diagnosis influence survival and treatment response in idiopathic pulmonary fibrosis? Real- world results from the EMPIRE registry. , 2017, , .		2
33	Prevalence of Latent Infection with Mycobacterium Tuberculosis in Interstitial Lung Diseases Using Interferon Gamma Release Assay. , 2017, , .		0
34	Analysis of comorbid conditions in 1210 IPF patients from the EMPIRE registry. , 2017, , .		0
35	Intercostal Artery - Pulmonary Artery Arterio-Arteriolar Fistula: A Case Report. Chest, 2016, 150, 1205A.	0.8	0
36	Pulmonary Hypertension in Interstitial Lung Disease: Ege University Experience. Chest, 2016, 150, 1178A.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Survival in CVD-ILD at Ege University Hospital. , 2016, , .		0
38	Neoplasia in patients with ILD; shortened survival. , 2016, , .		0
39	Sequencing of mutations in the serine/threonine kinase domain of the bone morphogenetic protein receptor type 2 gene causing pulmonary arterial hypertension. <i>Anatolian Journal of Cardiology</i> , 2015, 16, 491-496.	0.9	2
40	Variation in mortality from pulmonary hypertension by aetiology. , 2015, , .		0
41	Sarcoidosis Presenting with Membranous Nephropathy in a Patient with Hypertensive Nephropathy: Case Report. <i>Turkish Nephrology, Dialysis and Transplantation Journal</i> , 2015, 24, .	0.0	0
42	Variation in mortality from interstitial lung disease by diagnosis. , 2015, , .		0
43	A rare tumor of the lung: Pulmonary sclerosing hemangioma (pneumocytoma). <i>Respiratory Medicine</i> , 2013, 107, 448-450.	2.9	13
44	Erratum to "High dose rate endobronchial brachytherapy in the management of lung cancer: Response and toxicity evaluation in 158 patients" [Lung Cancer 62 (2008) 326-333]. <i>Lung Cancer</i> , 2009, 65, 128.	2.0	0
45	High dose rate endobronchial brachytherapy in the management of lung cancer: Response and toxicity evaluation in 158 patients. <i>Lung Cancer</i> , 2008, 62, 326-333.	2.0	40
46	Dynamic Computed Tomography in Solitary Pulmonary Nodules. <i>Journal of Computer Assisted Tomography</i> , 2008, 32, 222-227.	0.9	10
47	An Unusual Presentation of Anti-Jo-1 Syndrome, Mimicking Lung Metastases, With Massive Pleural and Pericardial Effusions. <i>Journal of Clinical Rheumatology</i> , 2006, 12, 90-92.	0.9	9
48	The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. <i>Respiratory Medicine</i> , 2005, 99, 1494-1500.	2.9	54
49	Comparison of echocardiographic markers of right ventricular function in determining prognosis in chronic pulmonary disease. <i>Journal of the American Society of Echocardiography</i> , 2002, 15, 633-639.	2.8	186
50	High dose rate endobronchial brachytherapy in combination with external beam radiotherapy for stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2001, 34, 253-259.	2.0	40
51	B-cell isotype control in atopy and asthma assessed with cDNA array technology. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2001, 280, L627-L637.	2.9	13
52	Pulmonary Function in Idiopathic Pulmonary Fibrosis and Referral for Lung Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 103-108.	5.6	222
53	Evaluation of CMV viral load using TaqMan??? CMV quantitative PCR and comparison with CMV Antigenemia in heart and lung transplant recipients. <i>Transplantation</i> , 2001, 71, 1609-1615.	1.0	85
54	Doppler Echocardiographic Index of Global Right Ventricular Function. <i>Circulation</i> , 2000, 101, E117.	1.6	4

#	ARTICLE	IF	CITATIONS
55	Intracardiac Thrombus in Behçet's Disease. Chest, 2000, 118, 479-487.	0.8	184
56	Pulmonary Langerhansâ€™ Cell Histiocytosis. Chest, 1999, 115, 1452-1455.	0.8	145
57	Acute Purulent Exacerbation of Chronic Obstructive Pulmonary Disease and <i>Chlamydia pneumoniae</i> Infection. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 349-353.	5.6	117
58	Endobronchial Metastasis From Osteosarcoma of Bone. Chest, 1999, 116, 1811-1814.	0.8	15